SARS-COV2 main protease inhibitors
US-12091420-B2 · Sep 17, 2024 · US
Sars-cov2 main protease inhibitors
US12410183B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12410183-B2 |
| Application number | US-202418743475-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 14, 2024 |
| Priority date | Aug 5, 2022 |
| Publication date | Sep 9, 2025 |
| Grant date | Sep 9, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present disclosure relates to compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.
First claim
Opening claim text (preview).
We claim: 1. A method of treating or preventing a viral infection in a human in need thereof, wherein the method comprises administering to the human a compound selected from or a pharmaceutically acceptable salt thereof. 2. The method of claim 1 , wherein the compound is or a pharmaceutically acceptable salt thereof. 3. The method of claim 1 , wherein the compound is or a pharmaceutically acceptable salt thereof. 4. The method of claim 1 , wherein the compound is or a pharmaceutically acceptable salt thereof. 5. The method of claim 1 , wherein the compound is or a pharmaceutically acceptable salt thereof. 6. The method of claim 1 , wherein the compound is or a pharmaceutically acceptable salt thereof. 7. The method of claim 1 , wherein the compound is or a pharmaceutically acceptable salt thereof. 8. The method of claim 1 , wherein the compound is or a pharmaceutically acceptable salt thereof. 9. The method of claim 1 , wherein the compound is or a pharmaceutically acceptable salt thereof. 10. The method of claim 1 , wherein the compound is or a pharmaceutically acceptable salt thereof. 11. The method of claim 1 , wherein the compound is or a pharmaceutically acceptable salt thereof. 12. The method of claim 1 , wherein the compound is or a pharmaceutically acceptable salt thereof. 13. The method of claim 1 , wherein the compound is or a pharmaceutically acceptable salt thereof. 14. The method of claim 1 , wherein the viral infection is a coronavirus infection. 15. The method of claim 4 , wherein the viral infection is a coronavirus infection. 16. The method of claim 5 , wherein the viral infection is a coronavirus infection. 17. The method of claim 11 , wherein the viral infection is a coronavirus infection. 18. The method of claim 1 , wherein the viral infection is caused by a virus having at least 70% sequence homology to a viral polymerase selected from SARS-CoV polymerase, MERS-CoV polymerase, and SARS-CoV-2. 19. The method of claim 4 , wherein the viral infection is caused by a virus having at least 70% sequence homology to a viral polymerase selected from SARS-COV polymerase, MERS-CoV polymerase, and SARS-CoV-2. 20. The method of claim 5 , wherein the viral infection is caused by a virus having at least 70% sequence homology to a viral polymerase selected from SARS-COV polymerase, MERS-CoV polymerase, and SARS-CoV-2. 21. The method of claim 11 , wherein the viral infection is caused by a virus having at least 70% sequence homology to a viral polymerase selected from SARS-COV polymerase, MERS-CoV polymerase, and SARS-CoV-2. 22. The method of claim 1 , wherein the viral infection is SARS-CoV-2 infection (COVID-19). 23. The method of claim 4 , wherein the viral infection is SARS-CoV-2 infection (COVID-19). 24. The method of claim 5 , wherein the viral infection is SARS-CoV-2 infection (COVID-19). 25. The method of claim 11 , wherein the viral infection is SARS-CoV-2 infection (COVID-19).
Assignees
Inventors
Classifications
Ortho-condensed systems · CPC title
Ortho-condensed systems · CPC title
with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring · CPC title
with only one oxygen atom as ring hetero atom in the oxygen-containing ring · CPC title
Spiro-condensed systems · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12410183B2 cover?
- The present disclosure relates to compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.
- Who is the assignee on this patent?
- Gilead Sciences Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D495/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Sep 09 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).